Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

This study reported the generation of aducanumab, a human monoclonal antibody designed to selectively target aggregated Aβ. In a transgenic mouse model of AD, aducanumab entered the brain, bound parenchymal Aβ, and reduced both soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions reduced brain Aβ and was accompanied by a slowing of clinical decline.

What this study adds

Evidence grade: Low

Reports that the antibody aducanumab reduces amyloid-beta plaques in Alzheimer's disease. Clearing plaques is a change in brain pathology, and this record does not state whether thinking or daily functioning improved with it.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L. J., Maier, M., et al. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. https://doi.org/10.1038/nature19323

Vancouver

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams LJ, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016. doi:10.1038/nature19323. PMID: 27582220.

BibTeX

@article{sevigny2016-27582220,
  author  = {Sevigny, Jeff and Chiao, Ping and Bussière, Thierry and Weinreb, Paul H. and Williams, Leslie J. and Maier, Marcel and Dunstan, Robert W. and Salloway, Stephen and others},
  title   = {{The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease}},
  journal = {Nature},
  year    = {2016},
  doi     = {10.1038/nature19323},
  pmid    = {27582220},
  url     = {https://doi.org/10.1038/nature19323}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Reports that the antibody aducanumab reduces amyloid-beta plaques in Alzheimer's disease. Clearing plaques is a change in brain pathology, and this record does not state whether thinking or daily functioning improved with it.

Study details

How this study scored 60/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 5 of 6; Still being cited 4 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 60 of 100.60 of 100 points earned40 not earned

Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (Nature)
Journal's citation record 4 / 4 Nature: journal h-index 1,841 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2016 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 3,050 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 254.2 citations a year over 12 year(s) since 2016
Impact for its field and year 6 / 6 Cited 183.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 5 / 6 Cited by 149 other studies in this library
Still being cited 4 / 4 Cited 901 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Alfred W. Sandrock: h-index 35 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Zurich: institution h-index 1,220 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 27582220)
Free to read 0 / 2 Behind a paywall — scores zero
Total 60 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.

Later studies that cite this one

149 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →